Quality & complianceOfficial

Queens SADC director pleads guilty to $127m Medicare and Medicaid fraud scheme

🇺🇸 US Department of Justice · Tue 10 Nov 2026

Daniel Lee admitted conspiracy to commit health care fraud and money laundering over claims for unnecessary prescription drugs and adult day care services never delivered, the US Justice Department said.

A Queens man has pleaded guilty to defrauding Medicare and New York State Medicaid of about $127 million, the US Department of Justice announced on 10 November 2026. The scheme involved billing for medically unnecessary prescription drugs and for social adult day care (SADC) services that were not provided.

According to court documents, Daniel Lee, 57, of Flushing, New York, was a program director at two Flushing SADC centres, Happy Life Inc. and Z&W Empire Enterprise, Inc., trading as Royal Adult Day Care Center. Over roughly ten years, the two businesses paid cash kickbacks and bribes to Medicaid recipients to enrol them, and billed Medicaid for services never delivered. Some claims covered days when recipients were in hospital and could not have attended.

Over the same period, Lee and his co-conspirators paid kickbacks and bribes to Medicare beneficiaries and Medicaid recipients at a related pharmacy. That pharmacy submitted claims for prescription drugs that were not medically necessary, the department said.

A search warrant at Happy Life turned up more than $100,000 in cash, and law enforcement seized about $900,000 in fraud proceeds from bank accounts. Lee pleaded guilty to conspiracy to commit health care fraud and conspiracy to commit money laundering. Sentencing is scheduled for 2 March 2027; the maximum penalty is 30 years in prison, and a federal district court judge will decide the sentence.

HHS-OIG, the FBI, IRS Criminal Investigation and OSC are investigating. The Justice Department added that its Health Care Fraud Strike Force Program, now nine strike forces, has charged more than 6,200 defendants since 2007 who collectively billed federal health care programmes and private insurers more than $45 billion.

What it means for your team

  • The case has no direct pharmacovigilance or product-safety implications, but it shows continued US enforcement focus on improper prescription drug billing.
  • Pharmacy-linked schemes involving kickbacks to beneficiaries remain a target for DOJ, HHS-OIG, the FBI and IRS-CI working together.
  • US-facing compliance and market-access teams may wish to review controls around pharmacy claims and any patient-inducement risks in their distribution and dispensing networks.

Official source: US Department of Justice ↗

Article written by VigiEye from the official source (US Department of Justice). AI-assisted; check the source before acting.

More Quality & compliance All →